Avramova B, Jordanova M, Konstantinov D, Hristozova I, Shtarbanov I, Bobev Dr
Specialized Children's Oncohaematology Hospital, Sofia, Bulgaria.
J BUON. 2011 Jul-Sep;16(3):551-6.
To compare the survival of patients with poor prognosis Ewing's sarcoma family tumors (EFT) after conventional and myeloablative chemotherapy treated at our hospital in a period of 25 years.
Fifty-seven patients were treated between 1985 and 2010. The patients were separated into 3 groups. Group A included patients (n=20) treated with conventional chemotherapy between 1985 and 1997. Group B patients (n=22) were treated with conventional chemotherapy protocols between 1997 and 2010; and group C patients (n=15) were treated in the same period of time with conventional chemotherapy and subsequent myeloablative chemotherapy with hematopoietic stem cell transplantation (HSCT).
In group A patients the 5-year overall survival (OS) was 25% and the disease-free survival (DFS) 15%; in group B patients they were 27.27% and 18.8% (p=0.31) and in group C patients 33.3% and 20% (p=0.58), respectively.
More intensive chemotherapy, including myeloablative chemotherapy plus HSCT, is a curative option for patients with poor-prognosis EFT, but the survival still remains unsatisfactory.
比较我院25年间接受传统化疗和清髓性化疗的预后不良尤因肉瘤家族肿瘤（EFT）患者的生存率。
1985年至2010年间治疗了57例患者。患者被分为3组。A组包括1985年至1997年间接受传统化疗的患者（n = 20）。B组患者（n = 22）在1997年至2010年间接受传统化疗方案治疗；C组患者（n = 15）在同一时期接受传统化疗及随后的清髓性化疗和造血干细胞移植（HSCT）。
A组患者的5年总生存率（OS）为25%，无病生存率（DFS）为15%；B组患者分别为27.27%和18.8%（p = 0.31），C组患者分别为33.3%和20%（p = 0.58）。
更强化的化疗，包括清髓性化疗加HSCT，是预后不良EFT患者的一种治愈选择，但生存率仍不尽人意。
